{"id":"trametinib-tablet","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Dermatologic reactions"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Hypophosphatemia"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Abdominal pain"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Rash"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This pathway is crucial for cell division and growth, and its dysregulation is associated with various cancers. By inhibiting MEK1 and MEK2, trametinib reduces tumor growth and proliferation.","oneSentence":"Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:42.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Unresectable or metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT06804824","phase":"PHASE1","title":"A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Vividion Therapeutics, Inc.","startDate":"2025-02-25","conditions":"Advanced Solid Tumors","enrollment":220},{"nctId":"NCT04417621","phase":"PHASE2","title":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-30","conditions":"Melanoma","enrollment":134},{"nctId":"NCT07440290","phase":"PHASE2, PHASE3","title":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Research UK","startDate":"2026-02","conditions":"Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders","enrollment":30},{"nctId":"NCT04201457","phase":"PHASE1, PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":"Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1","enrollment":57},{"nctId":"NCT03340506","phase":"PHASE4","title":"Dabrafenib and/or Trametinib Rollover Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-28","conditions":"Melanoma, Non Small Cell Lung Cancer, Solid Tumor","enrollment":100},{"nctId":"NCT04111458","phase":"PHASE1","title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2019-11-04","conditions":"Solid Tumors, KRAS Mutation; SOS1","enrollment":71},{"nctId":"NCT04294160","phase":"PHASE1","title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-22","conditions":"BRAF V600 Colorectal Cancer","enrollment":122},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT04940052","phase":"PHASE3","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":153},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT04892017","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-06-15","conditions":"Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":144},{"nctId":"NCT02967692","phase":"PHASE3","title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-02-17","conditions":"Melanoma","enrollment":568},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT06582745","phase":"PHASE2","title":"Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib","status":"RECRUITING","sponsor":"Cook Children's Health Care System","startDate":"2024-06-24","conditions":"Langerhans Cell Histiocytosis","enrollment":75},{"nctId":"NCT07072403","phase":"PHASE1, PHASE2","title":"Trametinib Treatment for Complicated Vascular Anomalies","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-07-07","conditions":"Vascular Anomalies","enrollment":20},{"nctId":"NCT02230553","phase":"PHASE1, PHASE2","title":"Lapatinib Plus Trametinib in KRAS Mutant NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-10-07","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT05440942","phase":"PHASE1","title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Peter Hosein, MD","startDate":"2023-01-19","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT03551626","phase":"PHASE3","title":"Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Malignant Melanoma","enrollment":552},{"nctId":"NCT02974725","phase":"PHASE1","title":"A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-02-24","conditions":"Non-Small Cell Lung Cancer, Melanoma","enrollment":241},{"nctId":"NCT02872259","phase":"PHASE1, PHASE2","title":"BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2017-02-13","conditions":"Melanoma","enrollment":74},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT06555237","phase":"PHASE2","title":"MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2024-08-01","conditions":"Cardiomegaly, Noonan Syndrome","enrollment":40},{"nctId":"NCT06098872","phase":"PHASE2","title":"Pilot Study on Trametinib for Surgical Unruptured AVMs","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2024-01-30","conditions":"Arteriovenous Malformations","enrollment":10},{"nctId":"NCT05071183","phase":"PHASE1, PHASE2","title":"A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors","status":"TERMINATED","sponsor":"Turning Point Therapeutics, Inc.","startDate":"2021-09-23","conditions":"KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":9},{"nctId":"NCT02684058","phase":"PHASE2","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-28","conditions":"Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma","enrollment":151},{"nctId":"NCT05876806","phase":"PHASE2","title":"Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations","status":"RECRUITING","sponsor":"Se Jun Park","startDate":"2023-06-20","conditions":"Cancer","enrollment":30},{"nctId":"NCT05370807","phase":"PHASE2","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-10-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":48},{"nctId":"NCT05988697","phase":"","title":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-11-01","conditions":"NSCLC, BRAF V600E Mutation, Advanced Cancer","enrollment":36},{"nctId":"NCT01682083","phase":"PHASE3","title":"Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-08","conditions":"Melanoma","enrollment":870},{"nctId":"NCT02034110","phase":"PHASE2","title":"Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-12","conditions":"Cancer","enrollment":206},{"nctId":"NCT03428126","phase":"PHASE2","title":"Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-21","conditions":"Malignant Neoplasms of Digestive Organs, Colorectal Cancer, Colon Cancer","enrollment":29},{"nctId":"NCT04258046","phase":"PHASE2","title":"Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation","status":"UNKNOWN","sponsor":"Stanford University","startDate":"2020-12-01","conditions":"Venous Malformation, Arterial Disease","enrollment":30},{"nctId":"NCT04326283","phase":"PHASE1, PHASE2","title":"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Genuv Inc.","startDate":"2020-04-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":23},{"nctId":"NCT02130466","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-29","conditions":"Melanoma, Solid Tumors","enrollment":184},{"nctId":"NCT01336634","phase":"PHASE2","title":"Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-05","conditions":"Cancer","enrollment":177},{"nctId":"NCT02900664","phase":"PHASE1","title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-23","conditions":"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma","enrollment":283},{"nctId":"NCT02705963","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-20","conditions":"Solid Tumors","enrollment":19},{"nctId":"NCT02083354","phase":"PHASE2","title":"Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-18","conditions":"Cancer, Melanoma","enrollment":77},{"nctId":"NCT01750918","phase":"PHASE1, PHASE2","title":"BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-19","conditions":"Cancer","enrollment":166},{"nctId":"NCT02124772","phase":"PHASE1, PHASE2","title":"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-01-15","conditions":"Cancer","enrollment":139},{"nctId":"NCT02110355","phase":"PHASE1","title":"A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma","status":"COMPLETED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2014-12-19","conditions":"Advanced Malignancy, Advanced Solid Tumors, Cancer","enrollment":31},{"nctId":"NCT04554680","phase":"PHASE2","title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2020-12-30","conditions":"Thyroid Cancer","enrollment":5},{"nctId":"NCT04644432","phase":"PHASE2","title":"Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Herlev and Gentofte Hospital","startDate":"2020-03-06","conditions":"Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms","enrollment":30},{"nctId":"NCT01938443","phase":"PHASE1","title":"A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-18","conditions":"Cancer, Neoplasms","enrollment":34},{"nctId":"NCT02039947","phase":"PHASE2","title":"Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-21","conditions":"Melanoma and Brain Metastases","enrollment":127},{"nctId":"NCT02027961","phase":"PHASE1","title":"Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-12-20","conditions":"Melanoma","enrollment":68},{"nctId":"NCT02016729","phase":"PHASE1","title":"A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2014-04-01","conditions":"Advanced Malignancy, Cancer, Oncology","enrollment":36},{"nctId":"NCT02314143","phase":"PHASE2","title":"Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-11-13","conditions":"Melanoma","enrollment":48},{"nctId":"NCT02258607","phase":"PHASE1","title":"Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase","status":"TERMINATED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2015-03-11","conditions":"Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT02447939","phase":"PHASE1","title":"Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-05","conditions":"Melanoma","enrollment":""},{"nctId":"NCT02939846","phase":"PHASE1","title":"Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-05","conditions":"Cancer","enrollment":""},{"nctId":"NCT01978236","phase":"PHASE2","title":"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-04-08","conditions":"Melanoma and Brain Metastases","enrollment":6},{"nctId":"NCT02065063","phase":"PHASE1","title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-22","conditions":"Cancer","enrollment":28},{"nctId":"NCT03266159","phase":"PHASE2","title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-11-27","conditions":"Solid Tumours","enrollment":""},{"nctId":"NCT01767454","phase":"PHASE1","title":"Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-12","conditions":"Solid Tumours","enrollment":38},{"nctId":"NCT01725100","phase":"PHASE1","title":"A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-05","conditions":"Cancer","enrollment":80},{"nctId":"NCT01658553","phase":"PHASE1","title":"A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-19","conditions":"Cancer","enrollment":60},{"nctId":"NCT01416337","phase":"PHASE1","title":"Absolute Bioavialability of GSK1120212","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-20","conditions":"Cancer","enrollment":6},{"nctId":"NCT01647659","phase":"PHASE1","title":"Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-30","conditions":"Cancer","enrollment":18},{"nctId":"NCT02416232","phase":"","title":"Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma","status":"NO_LONGER_AVAILABLE","sponsor":"GlaxoSmithKline","startDate":"","conditions":"Melanoma","enrollment":""},{"nctId":"NCT01943864","phase":"PHASE2","title":"A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-09-19","conditions":"Cancer","enrollment":20},{"nctId":"NCT02292732","phase":"PHASE1","title":"A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Cancer","enrollment":""},{"nctId":"NCT01938456","phase":"PHASE1","title":"Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":"Lung Cancer, Non-Small Cell","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"PYREXIA"},{"count":7,"reaction":"CHILLS"},{"count":4,"reaction":"SQUAMOUS CELL CARCINOMA"},{"count":3,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":3,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"SQUAMOUS CELL CARCINOMA OF SKIN"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ABDOMINAL PAIN"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Trametinib tablet","genericName":"Trametinib tablet","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway. Used for Metastatic melanoma, Unresectable or metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}